PR Newswire BiotechnologyCodex · 实盘不做把握 9/10
北京时间·🕒 发布 06:00:00时区推断·⟳ 抓取 06:02:56·⚡ 决策 07-29 06:03:26 +30s·90.9 天前
Nektar Therapeutics 宣布将于 2026年8月13日盘后披露二季度财报并召开电话会
本次只是财报披露时间和电话会安排通知，没有披露业绩、指引、临床数据、融资、监管或合作等新增经营事实。
📄 原文PR Newswire Biotechnology↗ 原文
SAN FRANCISCO, July 28, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for…
不做 Nektar Therapeutics（NKTR.US）
例行财报发布时间公告，没有披露业绩结果、指引变化或临床/监管进展，方向不明且无可交易 edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-28 · 扩散 low · price-in 风险 low ↗
关键理由
- 本次只是财报披露时间和电话会安排通知，没有披露业绩、指引、临床数据、融资、监管或合作等新增经营事实。
主要风险
- 若 8月13日实际财报或电话会披露超预期数据/管线进展，应由新信号重新研判。
原文全文
展开原文 · 2,021 字
SAN FRANCISCO, July 28, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2026 on Thursday, August 13, 2026, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.
This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: https://ir.nektar.com/. The web broadcast of the conference call will be available for replay through September 13, 2026.
To access the conference call, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in a registrational program in atopic dermatitis, being planned for a registrational program in alopecia areata, and being evaluated in one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar's pipeline also includes preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422.
Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow us on LinkedIn.
Contacts
For Investors:
Vivian Wu
628-895-0661
[email protected]
Corey Davis, Ph.D.
LifeSci Advisors
212-915-2577
[email protected]
For Media:
Susan Roberts
LifeSci Communications
202-779-0929
[email protected]
SOURCE Nektar Therapeutics
This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: https://ir.nektar.com/. The web broadcast of the conference call will be available for replay through September 13, 2026.
To access the conference call, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in a registrational program in atopic dermatitis, being planned for a registrational program in alopecia areata, and being evaluated in one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar's pipeline also includes preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422.
Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow us on LinkedIn.
Contacts
For Investors:
Vivian Wu
628-895-0661
[email protected]
Corey Davis, Ph.D.
LifeSci Advisors
212-915-2577
[email protected]
For Media:
Susan Roberts
LifeSci Communications
202-779-0929
[email protected]
SOURCE Nektar Therapeutics
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。